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therapy with everolimus versus BSC alone from the Canadian societal perspective.
METHODS: A Markov model simulated 2 hypothetical patient cohorts (everolimus
versus BSC alone) from the time of initial treatment throughout the 6-year time
horizon. The cost-effectiveness of everolimus was calculated in terms of cost per
life-years gained (LYG) as well as cost per quality-adjusted life year (QALY) gained.
Health state transition probabilities were derived directly from the RECORD-1 sub-
group analysis; costs and health state utility values were obtained from literature.
The analysis was performed from a societal perspective; as such, direct medical
costs and indirect costs associated with productivity loss due to morbidity or future
income loss attributed to early mortality were included. A sensitivity analysis from
the payer’s perspective was additionally performed. Outcomes and costs were dis-
counted at a 5% annual rate. RESULTS: Treatment with everolimus produced an
estimated gain over BSC alone of 0.643 LYG (0.455 QALYs) at an incremental cost of
$22,074. The deterministic analysis resulted in incremental cost-effectiveness ra-
tios (ICERs) of $34,326/LYG and $48,507/QALY. The payer’s perspective sensitivity
analysis resulted in ICERs of $48,670/LYG and $68,777/QALY. According to the prob-
abilistic sensitivity analysis, given a threshold of $100,000/QALY, the probability
that everolimus was cost-effective, from a societal perspective, was 100%.
CONCLUSIONS: Results of this analysis suggest that, from a Canadian societal
perspective, everolimus is a cost-effective alternative to BSC alone when treating
mRCC patients whose disease fails on one prior VEGF-TKI treatment.
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OBJECTIVES: Colorectal cancer (CRC) is the third most frequent worldwide and
about 28,110 new cases were expect for Brazil in 2010. Two biologic agents are
approved for treatment of mCRC in Brazil: cetuximab, exclusively for K-RAS wild-
type patients and bevacizumab, for both K-RAS types. We aimed to compare costs
and outcomes of bevacizumab versus cetuximab in first-line treatment of mCRC,
both in combination with FOLFIRI from a private payer perspective in Brazil.
METHODS: In the absence of head-to-head trials comparing BevFOLFIRI and
CetFOLFIRI, an adjusted indirect comparison was conducted using Bucher-
method. Hazard ratios (HRs) from 3 studies: BICC-C(part II) comparing BevFOLFIRI
vs BevIFL; AVF2107g comparing BevIFL vs IFL; and CRYSTAL comparing
CetFOLFIR versus FOLFIRI; were utilized. An illness-death Markov model was
enhanced. Risks for progression and mortality were derived from Weibull regres-
sion model (assuming deaths conditional upon prior progression). Natural mortal-
ity rates were applied according to IBGE life table. Only direct costs were considered
for patients with 1,78m2 and 70Kg. Ex-factory prices were obtained from official
public sources. Time-horizon was two years according to natural history of the
disease. Utilities were derived from international sources; discounting was 5% for
costs and outcomes, according to local guidelines. A probabilistic sensitivity anal-
ysis (PSA) was conducted in order to evaluate the robustness of results. Non-sta-
tistically significant HR 95%-CIs were exploited in PSA. RESULTS: Results of the
analysis suggest BevFOLFIRI combination is less costly compared to CetFOLFIRI
($Brz216,838.38 vs. $Brz276,770.15) and a trend towards improved effectiveness
with BevFOLFIRI (OS 20.1 vs. 16.60 months; QALYs 1.1 vs. 0.9) in first-line treat-
ment of mCRC. PSA portends that BevFOLFIRI is dominant over CetFOLFIRI
(93,44% of iterations BevFOLFIRI prolonged OS, being less costly). CONCLUSIONS:
Based on current available data, analysis suggest BevFOLFIRI presents lower costs
and better efficacy than CetFOLFIRI for treatment of first-line mCRC from a pri-
vate payer perspective in Brazil.
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OBJECTIVES: To determine the cost-effectiveness of erlotinib compared with do-
cetaxel every 3 weeks (D3W) or weekly (DW) or pemetrexed in second line treat-
ment for patients with advanced or metastatic NSCLC, from the Brazilian Private
Healthcare System perspective. METHODS: The analysis is based on a three stage
Markov model to estimate costs and consequences of treatments over 2 years.
Epidemiological and efficacy data were derived from a systematic literature search.
Indirect network meta-analysis assessed the relative efficacy of the compared
treatments. The survival curves were modeled by fitting a Weibull distribution.
Only direct medical costs were considered: Drug costs, daily hospital admission
rates, procedures and laboratory test unit cost were obtain from Brazilian official
databases of private healthcare system fees. Costs and benefits were discounted at
5% yearly and reported in 2010 Brazilian currency (BRL). Outcomes were expressed
as progression-free survival (PFS; months), overall survival (OS; months) and qual-
ity adjusted life years (QALY). Probabilistic sensitivity analysis (PSA) was conducted
to assess model robustness.RESULTS:Through the systematic literature review we
identified a network meta-analysis performed by Hawkins et al comparing BR21,
JMEI, TAX 317, ISEL, INTEREST and SIGN trials that formed the body of clinical data
for the analysis. The analysis showed higher clinical benefits and lower average
costs for erlotinib (9.73 OS; 4.24 PFS; 0.25 QALY; R$40,471) than D3W (8.49 OS; 3.21
PFS; 0.21 QALY; R$47,180) or DW (8.49 OS; 3.21 PFS; 0.21 QALY; R$56,549) or pem-
etrexed (8.49 OS; 3.31 PFS; 0.21 QALY; R$60,151), showing the dominance of erlo-
tinib related to compared treatments. PSA demonstrated that in 86%, 98% and 97%
of the simulations erlotinib was dominant compared to D3W, DW and pemetrexed.
CONCLUSIONS: This analysis portends that Erlotinib could be considered as a
dominant treatment strategy in 2nd line mNSCLC compared to docetaxel or pem-
etrexed under the Brazilian Private Healthcare System perspective.
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OBJECTIVES: The optimal intensity of conditioning prior to allogeneic hematopoi-
etic stem cell transplants (HSCT) remains uncertain. We present the result of the
prospective socio-economic evaluation associated with a randomized study com-
paring two levels of intensity reduction.METHODS:We compare reduced intensity
conditioning regimen (RIC Fludarabine, oral myleran and anti-thymocyte-globu-
lin) and non myeloablative conditioning regimen (NMAC Fludarabine and total
body irradiation). Direct medical transplant costs were estimated by micro-costing
on the basis of patients’ CRF until 18 months after transplant. Costs of treatment of
progression were estimated within five years after transplant. Cost-effectiveness
analysis was performed using overall survival (OS) and disease free survival (DFS)
as endpoint. Health-related quality of life (HRQL) was measured prospectively by
the EORTC QLQ-C30 questionnaire administered seven days before transplant and
on days 30 80 180 and 360. Linear mixed model analysis was performed to
test whether there were differences in HRQL outcomes within and between the two
groups over time. GVHD occurrence was included in the model. RESULTS:A total of
139 patients with hematological malignancies were treated (RIC: N69; NMAC:
N70). Survival and DFS at one and five years were identical after RIC and NMAC.
The mean total cost per patient was not different between groups (83,656€ for RIC
vs. 72,592€ for NMAC, NS). This is related to decreased post graft costs for NMAC
(-22,815€, p0.002) being offset by increased costs of disease progression (11,750€,
p0.008). Using DFS as endpoint, the RIC is cost-effective: incremental cost-effec-
tiveness ratio978.64 [95%IC313.23-2447.91]. Using OS no differences were found
between the two groups. RIC had a stronger negative impact on patients’ HRQL
independently of GVHD. CONCLUSIONS: The results confirmed the relapse/toxic-
ity arbitrage associated with the choice of the allo-HSCT conditioning regimen.
Moreover, the importance of the choice of endpoints and follow-up times in the
economic evaluation of cancer treatment is highlighted.
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OBJECTIVES: Maintenance treatment with Rituximab of follicular lymphoma (FL)
patients responding to first-line induction therapy with R-CHOP, R-CVP or R-FCM,
increases progression-free survival (hazard ratio 0.55; 95% CI 0.44 to 0.68, P0.0001)
compared with observation. We performed a cost-effectiveness analysis of main-
tenance therapy in first line of the FL with rituximab, compared with the option of
wait and watch strategy. METHODS: We developed a Markov model of the FL,
with four health states (progression free survival in first or second line, progression
and death). The transition probabilities between states were obtained from clinical
trials PRIMA and EORTC 20981. Health state utilities were obtained from literature.
The use of health resources, from the perspective of the National Health System
was estimated by a panel of Spanish onco-hematologist experts. Unitary costs (€ in
2010) were obtained from Spanish sources. Deterministic and probabilistic analy-
ses were performed. RESULTS: In the deterministic base case analysis, for a time
horizon of 30 years, the incremental cost per life year gained (LYG) and quality-
adjusted life-years (QALYs) gained, was €5663 and €6253 respectively. The sensi-
tivity analyses confirmed the stability of the base case for time horizons of 10 and
20 years and various statistical distributions (Weibull, exponential, log-logistic,
log-normal, Gompertz, and gamma) ranging between €4222 and €8766.
CONCLUSIONS: Compared with observation, rituximab maintenance treatment of
the FL that responds to inmunochemotherapy induction in first line, is a cost-
effective strategy.
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OBJECTIVES: Combinations of chemotherapy and monoclonal antibodies (MAbs)
against the vascular endothelial growth factor (bevacizumab) and the epidermal
growth factor receptor (cetuximab) have been shown to improve the clinical out-
come of patients with mCRC. Little is known about the economic implications of
their use. The aim of this analysis was to evaluate the cost, clinical- and cost-
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